A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...

PDAC, an aggressive and often difficult-to-diagnose cancer, frequently spreads before detection. The study, published in the ...

In recent study, PAC-MANN identified pancreatic ductal adenocarcinoma samples with 98 percent specificity and 73 percent sensitivity across all stages.

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the critical federal funding at risk and what this ...

Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation ...

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...

A new study from Memorial Sloan Kettering Cancer Center has shown that an RNA-based neoantigen vaccine can generate ...